Literature DB >> 19332268

Progressive multifocal leukoencephalopathy following heightened immunosuppression after lung transplant.

Jesse Waggoner1, Tereza Martinu, Scott M Palmer.   

Abstract

Progressive multifocal leukoencephalopathy (PML) is a rare demyelinating disease of the central nervous system caused by the JC virus that occurs in the setting of immunosuppression. A 38-year-old female lung transplant recipient at our institution received treatment for episodes of acute rejection with steroids, anti-thymocyte globulin and alemtuzumab, in addition to maintenance immunosuppression. She was diagnosed with PML 13 months after the last episode of rejection, for which she had received alemtuzumab. Despite attempted treatment with cidofovir followed by mirtazapine, PML progressed, and she ultimately died of an acute pulmonary infection and respiratory failure. We provide a detailed clinical and radiographic description of PML in a lung transplant patient and highlight its potential relationship to intensive immunosuppression, as the disease developed in the setting of markedly reduced CD4 counts.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19332268      PMCID: PMC3727631          DOI: 10.1016/j.healun.2008.12.010

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  20 in total

1.  Treatment of refractory acute rejection in a lung transplant recipient with campath 1H.

Authors:  B Diane Reams; R Duane Davis; Julia Curl; Scott M Palmer
Journal:  Transplantation       Date:  2002-09-27       Impact factor: 4.939

2.  Progressive multifocal leuko-encephalopathy; a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin's disease.

Authors:  K E ASTROM; E L MANCALL; E P RICHARDSON
Journal:  Brain       Date:  1958-03       Impact factor: 13.501

Review 3.  Progressive multifocal leukoencephalopathy in transplant recipients.

Authors:  David Shitrit; Nirit Lev; Ariella Bar-Gil-Shitrit; Mordechai R Kramer
Journal:  Transpl Int       Date:  2004-12-23       Impact factor: 3.782

4.  Monoclonal antibody therapy with CAMPATH-1H in patients with relapsed high- and low-grade non-Hodgkin's lymphomas: a multicenter phase I/II study.

Authors:  M Uppenkamp; A Engert; V Diehl; D Bunjes; D Huhn; G Brittinger
Journal:  Ann Hematol       Date:  2001-12-14       Impact factor: 3.673

5.  Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy.

Authors:  B L Padgett; D L Walker; G M ZuRhein; R J Eckroade; B H Dessel
Journal:  Lancet       Date:  1971-06-19       Impact factor: 79.321

6.  Diagnostic value of detecting JC virus DNA in cerebrospinal fluid of patients with progressive multifocal leukoencephalopathy.

Authors:  I W Fong; C B Britton; K E Luinstra; E Toma; J B Mahony
Journal:  J Clin Microbiol       Date:  1995-02       Impact factor: 5.948

7.  A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients.

Authors:  R Ally; D Schürmann; W Kreisel; G Carosi; K Aguirrebengoa; B Dupont; M Hodges; P Troke; A J Romero
Journal:  Clin Infect Dis       Date:  2001-09-26       Impact factor: 9.079

8.  JC virus DNA is present in many human brain samples from patients without progressive multifocal leukoencephalopathy.

Authors:  F A White; M Ishaq; G L Stoner; R J Frisque
Journal:  J Virol       Date:  1992-10       Impact factor: 5.103

9.  A reversible posterior leukoencephalopathy syndrome.

Authors:  J Hinchey; C Chaves; B Appignani; J Breen; L Pao; A Wang; M S Pessin; C Lamy; J L Mas; L R Caplan
Journal:  N Engl J Med       Date:  1996-02-22       Impact factor: 91.245

10.  Progressive multifocal leukoencephalopathy in a lung transplant recipient.

Authors:  David Shitrit; Lev Nirit; Sheely I Shiran; Gabriel Izbicki; Dov Sofer; Melamed Eldad; Mordechai R Kramer
Journal:  J Heart Lung Transplant       Date:  2003-08       Impact factor: 10.247

View more
  17 in total

Review 1.  Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis--establishing disease prognosis and monitoring patients.

Authors:  Mike P Wattjes; Àlex Rovira; David Miller; Tarek A Yousry; Maria P Sormani; Maria P de Stefano; Mar Tintoré; Cristina Auger; Carmen Tur; Massimo Filippi; Maria A Rocca; Franz Fazekas; Ludwig Kappos; Chris Polman
Journal:  Nat Rev Neurol       Date:  2015-09-15       Impact factor: 42.937

Review 2.  Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis.

Authors:  Jens Ingwersen; Orhan Aktas; Hans-Peter Hartung
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

3.  Monoclonal antibodies and progressive multifocal leukoencephalopathy.

Authors:  Joseph R Berger; Sidney A Houff; Eugene O Major
Journal:  MAbs       Date:  2009 Nov-Dec       Impact factor: 5.857

4.  Progressive multifocal leukoencephalopathy in a patient with chronic lymphocytic leukaemia treated with alemtuzumab.

Authors:  Luís Isidoro; Paula Pires; Luís Rito; Gustavo Cordeiro
Journal:  BMJ Case Rep       Date:  2014-01-08

5.  Fab-arm exchange.

Authors:  Ellen Broug; Philip A Bland-Ward; John Powell; Kevin S Johnson
Journal:  Nat Biotechnol       Date:  2010-02       Impact factor: 54.908

6.  Progressive multifocal leukoencephalopathy in transplant recipients.

Authors:  Farrah J Mateen; RajaNandini Muralidharan; Marco Carone; Diederik van de Beek; Daniel M Harrison; Allen J Aksamit; Mary S Gould; David B Clifford; Avindra Nath
Journal:  Ann Neurol       Date:  2011-08       Impact factor: 10.422

7.  A risk classification for immunosuppressive treatment-associated progressive multifocal leukoencephalopathy.

Authors:  Salim Chahin; Joseph R Berger
Journal:  J Neurovirol       Date:  2014-11-18       Impact factor: 2.643

Review 8.  Treatment-related progressive multifocal leukoencephalopathy: current understanding and future steps.

Authors:  Fariha Zaheer; Joseph R Berger
Journal:  Ther Adv Drug Saf       Date:  2012-10

Review 9.  Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use.

Authors:  Eva Havrdova; Dana Horakova; Ivana Kovarova
Journal:  Ther Adv Neurol Disord       Date:  2015-01       Impact factor: 6.570

Review 10.  Infection risk in patients on multiple sclerosis therapeutics.

Authors:  Eric M Williamson; Joseph R Berger
Journal:  CNS Drugs       Date:  2015-03       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.